Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2024-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding multiple reports and proposals related to the company's 2023 annual activities and the 2024 first quarter report. It references the 2023 Annual Report, 2023 Annual Financial Statements audited by an accounting firm, 2023 Supervisory Board Work Report, 2023 Internal Control Self-Evaluation Report, profit distribution plan, audit fees, and the 2024 Q1 report. The document itself does not contain the full financial statements or detailed financial data but rather summarizes the approval of these reports and states that the full reports are available on the designated disclosure website. The document length is 3701 characters, which is relatively short and consistent with an announcement of resolutions and approvals rather than the full reports themselves. According to the MENU VS MEAL rule, this is an announcement of the Supervisory Board's resolutions approving various reports and proposals, not the reports themselves. Therefore, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not contain the full report content.
2024-04-25 Chinese
中航证券有限公司关于公司2023年度定期现场检查报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2023年度定期现场检查报告" which translates to "2023 Annual Regular On-site Inspection Report" by Zhonghang Securities Co., Ltd. regarding Jianfan Biotechnology Group Co., Ltd. The content details a comprehensive on-site inspection covering company governance, internal control, information disclosure, use of raised funds, performance, shareholder commitments, and other important matters. It includes detailed findings and compliance checks but does not contain financial statements or typical annual report content. The document length is 4072 characters, which is relatively short and focused on inspection results rather than full financial disclosures. This type of document is a regulatory or compliance inspection report rather than an annual report, audit report, or earnings release. It fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance document reporting inspection results and does not constitute a full financial report or other specific filing types.
2024-04-25 Chinese
关于回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the company's repurchase and cancellation of a portion of restricted shares under a 2021 restricted stock incentive plan. It includes specifics about board and supervisory meetings, legal opinions, share quantities, prices, and the impact on share capital structure. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a corporate announcement about share repurchase and cancellation activities related to stock incentives. This fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2024-04-25 Chinese
2023年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2023 of 健帆生物科技集团股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statements including balance sheets, income statements, cash flow statements, and equity changes. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the document fits the category of Audit Report / Information (AR). FY 2023
2024-04-25 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告全文" (2023 Annual Report Full Text) of 健帆生物科技集团股份有限公司, which translates to Jafron Biomedical Co., Ltd. It contains detailed financial data, management discussion and analysis, company information, accounting policies, and extensive narrative on business operations and industry context. The document includes audited financial statements, auditor's report references, and comprehensive disclosures typical of a full annual report. The length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-25 Chinese
关于董事、监事、高级管理人员2023年薪酬的确定及2024年薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the determination of the 2023 remuneration and the 2024 remuneration plan for the company's directors, supervisors, and senior management. It includes detailed salary figures and the remuneration scheme for the upcoming year. The document is a formal disclosure of compensation information rather than a full annual report or financial statement. It does not contain financial results or operational data but focuses solely on remuneration details. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length is 2344 characters, which is consistent with a detailed remuneration announcement rather than a full report or a brief notice. Therefore, the appropriate classification is DEF 14A with high confidence.
2024-04-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.